Are variants in LDLR, APOB, or PCSK9 the primary cause of familial hypercholesterolemia?

Familial hypercholesterolemia (FH) is a monogenic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) from birth. In the majority of monogenic cases, the condition is driven by specific pathogenic variants that disrupt the body's natural ability to clear cholesterol from the bloodstream.

Clinical and Genetic Evidence

The genetic landscape of FH is well-defined, with mutations in three primary genes accounting for the vast majority of cases.

• LDLR variants: Mutations in the LDLR gene are the most common cause, identified in approximately 80% of confirmed monogenic FH cases globally.
• APOB and PCSK9 variants: Mutations in APOB are the second most frequent cause. Gain-of-function variants in PCSK9 are significantly rarer, found in 0% to 7.8% of cohorts depending on the population.
• Disease Risk: These genetic variants are associated with a 1.3-fold increased risk of ischemic heart disease due to the cumulative, lifelong exposure to high LDL-C levels.

Mechanistic Explanations

The primary physiological defect in FH is the impairment of hepatic LDL receptor-mediated clearance, which occurs through three distinct molecular pathways:

• Receptor Dysfunction (LDLR): Pathogenic variants can cause receptor misfolding and retention in the endoplasmic reticulum (Class 2), impair the receptor’s ability to bind LDL particles at the cell surface (Class 3), or disrupt the internalization of the receptor-LDL complex into the hepatocyte (Class 4).
• Ligand Binding Defects (APOB): Known as Familial Ligand-Defective Apolipoprotein B, these mutations alter the binding domain of the LDL particle itself. For example, mutations at residue Arg3527 can reduce binding affinity to approximately 63% of normal, preventing the receptor from capturing the LDL particle even when receptor function is otherwise normal.
• Accelerated Receptor Degradation (PCSK9): Gain-of-function mutations in PCSK9 lead to increased binding of the PCSK9 protein to the LDL receptor. This redirects the receptor away from its normal recycling pathway and toward lysosomal degradation, effectively reducing the density of available receptors on the liver cell surface.

Impact on Cholesterol Levels

The failure of these clearance mechanisms leads to a measurable decrease in the fractional catabolic rate (FCR)—the rate at which the body removes LDL particles from circulation.

• Clearance vs. Production: While some kinetic studies in heterozygous FH suggest that increased LDL production may also contribute to the total cholesterol burden, the fundamental defect remains the inability to increase the clearance rate in response to the larger LDL pool.
• Therapeutic Validation: The causal link is further supported by the efficacy of modern therapies like evinacumab, which lowers LDL-C by bypassing these defective LDLR pathways to enhance alternative clearance mechanisms.

Bottom line

Familial hypercholesterolemia is primarily caused by variants in LDLR, APOB, or PCSK9. These mutations drive very high LDL cholesterol by reducing the liver's capacity to clear LDL from the blood, either through direct receptor failure, impaired binding, or accelerated receptor degradation.